Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009.

Echo’s pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with data from the “YSI Glucose Analyzer. The study will obtain about 900 data pairs for use in the analyses. The study will be blind to participating subjects and personnel working on the project and will include reference glucose measurements made at roughly 15 minute intervals for 24 hours.

Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics commented, “We are extremely pleased to take this next step forward in the development work on our one piece biosensor, a critical component of Symphony, our needle-free, continuous glucose monitoring technology. As we described previously, this next generation biosensor introduces new materials and a more effective geometrical construction designed to be one-piece and replaces the prior prototype two-piece biosensor used in earlier clinical trials. We believe that this biosensor will demonstrate improved performance and reliability and we look forward to confirming this in this clinical trial in Type 1 and Type 2 diabetics.”

Echo Therapeutics is a company focusing on medical devices and specialty pharmaceuticals. The company is currently developing the Symphony tCGM System, a non-invasive, wireless, transdermal continuous glucose monitoring system. The product is targeted to patients with diabetes and hospital critical care units. Echo is also developing a needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of topical reformulations for widely-used, FDA-approved products.